Aimee Payne, M.D., Ph.D.
Dr. Payne is a Professor of Dermatology, Director of the Penn Clinical Autoimmunity Center of Excellence and the lead physician in the Autoimmune Blistering Clinic at the University of Pennsylvania, one of the largest tertiary referral centers for autoimmune blistering diseases in the United States. Her research laboratory has contributed to three major areas of investigation: 1) cloning and characterization of B cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; and 3) clinical-translational research to better understand current diagnostic tests and treatments and to develop novel targeted therapies for disease. In collaboration with Dr. Milone, her laboratory pioneered the CAAR T cell therapy concept for targeted depletion of autoreactive B cells that forms the foundation for Cabaletta Bio.
Dr. Payne also serves as Associate Director of the Medical Scientist Training Program, Core Director for the Skin Biology and Diseases Resource-based Center at the University of Pennsylvania and Chair of the NIH/NIAMS Board of Scientific Counselors. She serves on the Medical Advisory Council of the International Pemphigus and Pemphigoid Foundation (IPPF), which focuses on patient advocacy and education. Dr. Payne’s work in the field has been recognized with the Charles and Daneen Stiefel Scholar Award in Autoimmune Diseases, a Top 10 Clinical Research Forum Award, and election to the American Society of Clinical Investigation. She received her B.S. degree in Biology from Stanford University and an M.D./Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine prior to training in dermatology at the University of Pennsylvania.
Michael C. Milone, M.D., Ph.D.
Dr. Milone is currently an Associate Professor of Pathology and Laboratory Medicine and founding member of the Center for Cellular Immunotherapies at the University of Pennsylvania. He has more than 20 years of experience in immunology and more than 15 years of experience in the development of genetically-engineered T cell therapies including a post-doctoral fellowship with Carl June, M.D. from 2004 – 2007. He is a co-inventor of CTL019 (tisagenlecleucel), the first chimeric antigen receptor (CAR)-based T cell therapy to reach regulatory approval in the US and Europe, as well as several new CAR-T cell therapies for multiple myeloma and solid tumors that are currently in early phase clinical trials. Dr. Milone leads a team of translational researchers in the development of novel genetically engineered T cells for adoptive T cell immunotherapy.
Dr. Milone is a graduate of the accelerated B.S-M.D. program between Stevens Institute of Technology and New Jersey Medical School. He holds a B.S. in Chemical Biology from the Stevens and received his M.D. and Ph.D. degree in experimental pathology in 1999 from the University of Medicine and Dentistry of New Jersey (now part of Rutgers). He is a board-certified pathologist, completing an internship in Internal Medicine, residency in Clinical Pathology and fellowship training in Transfusion Medicine at the Hospital of the University of Pennsylvania. He continues to maintain a clinical practice as the Associate Director of the Toxicology Laboratory at the Hospital of the University of Pennsylvania and has received several awards for his excellence in teaching and research.
Jay Siegel, M.D.
Dr. Siegel is the current Chair of the National Academies' Forum on Regenerative Medicine and recently retired Chief Biotechnology Officer and Head of Scientific Strategy and Policy at Johnson & Johnson (J&J). He joined J&J as President of Research and Development, Centocor. He was subsequently promoted through multiple operational roles including Group President of R&D with oversight of biotechnology, immunology, and oncology, with responsibility for the successful discovery and development of several pharmaceutical products including STELARA®, SIMPONI®, SYLVANT® and most indications for REMICADE®. Dr. Siegel later served as head of global regulatory affairs and biotechnology for Janssen, the pharmaceutical companies of J&J. Dr. Siegel currently chairs the National Academies’ Forum on Regenerative Medicine, which is focused on cellular therapies, and a member of the Forum on Microbial Threats. He also served on the Executive Committees and the Boards of Directors of BIO and the Alliance for Regenerative Medicine. Prior to joining J&J, Dr. Siegel had a distinguished career for 20 years at the U.S. Food and Drug Administration Center for Biologics Evaluation and Research in positions of increasing responsibility including directing the office responsible for review and approval of all therapeutic biologics.
He was elected to fellowship in the American College of Physicians and the Society for Clinical Trials and has authored numerous publications in the areas of clinical trial design, biotechnology, immunology, and drug development policy. Dr. Siegel received a B.S. in Biology from the California Institute of Technology and M.D. from Stanford University. He trained in Internal Medicine at the University of California, San Francisco, and in Infectious Diseases and Immunology at Stanford University. Dr. Siegel is the recipient of numerous honors including the United States Public Health Service’s highest honor, the Distinguished Service Medal and, twice, the U.S. Health & Human Services Secretary’s Award for Distinguished Service.
Carl June, M.D.
Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently director of the Center for Cellular Immunotherapies and director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings, which represented the first successful and sustained demonstration of the use of gene transfer therapy to treat cancer. In 2017, it became the first Food and Drug Administration approved Chimeric Antigen Receptor (CAR) T cell therapy.
Dr. June has published more than 500 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine and the National Academy of Sciences, the William B. Coley award, the Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Hamdan Award for Medical Research Excellence and the Paul Ehrlich and Ludwig Darmstaedter Prize. In 2014, he was elected to the American Academy of Arts and Sciences. He is a graduate of the Naval Academy in Annapolis and Baylor College of Medicine in Houston, 1979. He had graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland in 1978 and 1979, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 to 1986. He is board certified in Internal Medicine and Medical Oncology.
Iain McInnes, FRCP, Ph.D.
Dr. McInnes is the Muirhead Professor of Medicine and Versus Arthritis Professor of Rheumatology in the University of Glasgow, Glasgow, United Kingdom. He is Director of the Versus Arthritis Centre of Excellence for Inflammatory Arthritis. He serves also as the Scientific Director of the Clinical Trials Unit for Greater Glasgow and Clyde Health Board. He is immediate past chairman of the Foreum (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap program that is defining the research agenda for European rheumatology for the next decade and is currently President of the European League Against Rheumatism (EULAR), the leading trans-national society for rheumatology across Europe. Under these auspices he is creating the first pan-European Rheumatology Research Centre planning to launch in 2021. His work is mainly focused upon the understanding of the pathogenesis of immune mediated inflammatory diseases and encompasses basic discovery immunology through phase 1 and proof of concept experimental medicine clinical trials to leadership of pivotal phase 3 trials in the area of immune biology. His laboratory group performed original discovery work leading to the therapeutic targeting of a several inflammatory cytokines. More recently he has focused on the biology of myeloid cells in the pathogenesis of a number of immune diseases. He has published more than 400 peer-reviewed original and review articles. He is a Fellow of the Royal Society of Edinburgh and Fellow of the Academy of Medical Sciences. He was made Commander of the Order of the British Empire (CBE) in 2019 by HM Queen Elizabeth II.